deltatrials
Completed PHASE4 NCT02768571

Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke

Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Patients With Severe Motor Involvement at Subacute Phase of Stroke

Sponsor: Ever Neuro Pharma GmbH

Conditions Stroke
Interventions Cerebrolysin Placebo
Updated 7 times since 2017 Last updated: Sep 18, 2019 Started: Mar 14, 2016 Primary completion: Feb 14, 2019 Completion: Feb 14, 2019

This PHASE4 trial investigates Stroke and is currently completed. Ever Neuro Pharma GmbH leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE4

  5. Oct 2019 — Jan 2021 [monthly]

    Completed PHASE4

    Status: Unknown Status → Completed

▶ Show 2 earlier versions

  1. Jun 2018 — Oct 2019 [monthly]

    Unknown Status PHASE4

    Status: Recruiting → Unknown Status

  2. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE4

    First recorded

Mar 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ever Neuro Pharma GmbH
  • Samsung Medical Center
Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Seoul, South Korea